一致Ｂ：2019年半年度报告（英文版）.PDF

1、China NationalAccord Medicines Corporation Ltd.Semi-Annual Report 2019August 20191Section I.Important Notice,Contents and ParaphraseBoard of Directors,Supervisory Committee,all directors,supervisors and seniorexecutives of China National Accord Medicines Corporation Ltd.(hereinafterreferred to as th

2、e Company)hereby confirm that there are no any fictitiousstatements,misleading statements,or important omissions carried in this report,and shall take all responsibilities,individual and/or joint,for the reality,accuracy and completion of the whole contents.Lin Zhaoxiong,Principal of the Company,Wei

3、 Pingxiao,person in charger ofaccounting works and Wang Ying,person in charge of accounting organ(accounting principal)hereby confirm that the Financial Report of Semi-Annual Report 2019 is authentic,accurate and complete.All directors are attended the Board Meeting for report deliberation.The Compa

4、ny plans not to pay cash dividends,bonus and carry out capitalizingof common reserves.2ContentsSection I Important Notice and Paraphrase.1Section II Company Profile and Main Financial Indexes.4Section III Summary of Company Business.7Section IV Discussion andAnalysis of Business.11Section V Importan

5、t Events.28Section VI Changes in Shares and Shareholders.58Section VII Preferred Stock.63Section VIII Particulars about Directors,Supervisors and Senior Executives.64Section IX Corporate Bonds.65Section X Financial Report.66Section XI Documents Available for Reference.2563ParaphraseItemsRefers toCon

6、tentsListedCompany,Company,theCompany,SinopharmAccord,the GroupRefers to China National Accord Medicines Corporation Ltd.SinopharmRefers toChina National Pharmaceutical Group CorporationSinopharm HoldingRefers to Sinopharm Group Co.,Ltd;Controlling shareholder of the CompanyCompany LawRefers to Comp